Agios Pharmaceuticals (AGIO) Total Non-Current Liabilities (2012 - 2026)

Agios Pharmaceuticals' Total Non-Current Liabilities history runs 11 years deep, the most recent figure standing at $75.8 million for Q1 2026.

• Quarterly Total Non-Current Liabilities fell 13.99% year-over-year to $75.8 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $75.8 million (down 13.99% YoY) and the FY2025 annual result came in at $104.0 million, down 14.29% from the prior year.
• Total Non-Current Liabilities was $75.8 million for Q1 2026 at Agios Pharmaceuticals, down from $104.0 million in the prior quarter.
• Across five years, Total Non-Current Liabilities topped out at $164.0 million in Q3 2024 and bottomed at $75.8 million in Q1 2026.
• A 5-year average of $115.0 million and a median of $116.4 million in 2023 frame the typical range for Total Non-Current Liabilities.
• Annual changes were most pronounced in 2024 — Total Non-Current Liabilities soared 37.49% — and 2025, when it tumbled 38.23%.
• Agios Pharmaceuticals' Total Non-Current Liabilities stood at $134.6 million in 2022, then fell by 7.19% to $124.9 million in 2023, then retreated by 2.87% to $121.4 million in 2024, then dropped by 14.29% to $104.0 million in 2025, then dropped by 27.14% to $75.8 million in 2026.
• Business Quant data shows AGIO's Total Non-Current Liabilities at $75.8 million in Q1 2026, $104.0 million in Q4 2025, and $101.3 million in Q3 2025.